IFNA2 and COVID-19: Roughly, 10% of coronavirus disease 2019 (COVID‐19) patients with severe pneumonia produce neutralizing autoantibodies against IFN‐α, IFN‐ω, or both, while patients with no or mild disease have no detectable autoantibodies [4].